Grant Thornton is one of the world's leading organisations for independent assurance, tax and advisory. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Luke Ritchie, Partner & National Head of Retail and Consumer Products at Grant Thornton Australia about the implications of Covid-19 on the Australian discretionary retail market. 

Boardroom Media

Grant Thornton: How retailers are responding to Covid-19

Grant Thornton is one of the world's leading organisations for independent assurance, tax and advisory. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Tony Markwell, National Managing Partner of Private Advisory at Grant Thornton. They talk about the light at the end of the COVID-19 tunnel, and how we can harness culture and innovation to do things differently in the ‘new normal’.

Grant Thornton: Harnessing opportunity in the time of COVID-19

Grant Thornton is one of the world's leading organisations for independent assurance, tax and advisory. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Madeleine Mattera, National Head of Financial Services at Grant Thornton. They discuss the current COVID-19 crisis and the role of the Financial Services sector in supporting the economy.

Grant Thornton: The role of financial services in supporting the economy

Grant Thornton is one of the world's leading organisations of independent assurance, tax and advisory firms. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Said Jahani, National Managing Partner - Financial Advisory of Grant Thornton. They discuss COVID-19: how it’s impacting the business world, how various sectors are dealing with the impacts, and how they should be preparing.

Grant Thornton: COVID-19 impacts the business world

Holista CollTech (ASX: HCT) today announced that it has filed its 100%-owned global patent for platform technology that will deliver many fat-soluble medications by creating a water-soluble delivery system. This patented process can apply to a whole range of molecules including the Cannabidiol (CBD) oil industry.

ASX:HCT - Holista CollTech files patent for water-soluble Cannabidiol technology

Openpay Group Ltd (OPY) is a payments technology company that offers a buy now, pay later (BNPL) product and is headquartered in Melbourne, Australia. Openpay provides a payments platform that facilitates seamless, secure and swift payments between Customers and Merchants. The Openpay platform allows Customers to make in-store and online purchases, and effectively split the payment for these purchases into multiple repayments over time, while attracting no interest.

ASX:OPY Michael Eidel briefs market on future growth plans

Business Journalist Velvet-Belle Templeman speaks to Paul Hopper, the Executive Chairman of SUDA Pharmaceuticals Ltd (ASX: SUD). The company, a leader in oro-mucosal drug delivery, announced that it has entered into a fully-funded feasibility study and option agreement with Spanish pharmaceutical company Laboratorios Ordesa, S.L., (Ordesa). Hopper discusses product commercialisation, exciting developments in their Cancer project, the role of the company's new CEO as well as insights for shareholders in the next 6 months.

ASX:SUD - SUDA signs deal with Ordesa, appoints new CEO and has Cancer project in the pipeline

Regeneus Ltd (ASX: RGS) a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc (AGC) to terminate their exclusive manufacturing licence and joint venture agreement.

ASX:RGS - Regeneus AGC Agreement termination paves way for commercial partner

As the U.S. prepares to pass the historic US Farm Bill, which includes the legalisation of industrial hemp, Elixinol Global CEO Paul Benhaim discusses the implications for the business and how the legislation change will support the company’s plans to expand its market operations.

Elixinol Global set to benefit from nearing of US Farm Bill legislation

Medlab Clinical Ltd (ASX: MDC) remains uniquely positioned as a fundamentally corner-stoned company in medical research but increasingly delivering a successful path to commercialisation in its Nutraceutical and Cannabis based products.

ASX: MDC - Operations Update - Strong Increase in Revenue

Medlab Clinical Ltd (ASX: MDC) is pleased to announce the NanoCBD™ update. Medlab’s NanoCBD™ product has been developed out of our US operations, with manufacturing underway at a licenced FDA facility, and has already received its first export order and deposit for 1,500 units to Hong Kong.

ASX:MDC - Medlab NanoCBD Update - First Export Order Received

Boardroom.Media speaks to Medlab Clinical Limited (ASX:MDC) CEO Sean Hall about Cannabis acting in the world of traditional pharmaceuticals. Medlab is an Australian life science company listed on the Australian Securities Exchange specialising in novel therapeutic discoveries to counter today’s chronic disease and improve quality of life. Medlab stands in the medical and pharmacy community that supports and promotes the health and safety of drug availability on the Australian market.

Cannabis: A real emerging field in the Market

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based specialist Medical Cannabis company with its principal business goal to produce and supply high quality Cannabinoid based products for the emergent medical markets in Europe, North America and Australasia. The company is built on the vision to be an international pioneer in the biopharmaceutical industry. We discussed the booming Cannabis market and why investors should consider cannabis stocks today.

Medical Cannabis: Why we should invest in cannabis stocks now

Boardroom.Media speaks to MMJ Group Holdings Limited (MMJ) director Mike Curtis about the future of the Cannabis market. MMJ Group Holdings Limited owns a portfolio of cannabis sector investments. MMJ aims to invest across the full range of cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D and retail. The legal market in Canada is fully recreational and it is a highly regulated market. MMJ is expecting Australia to be focused in the medicinal market, focusing generally on the clinics. MMJ looks to the higher quality regulated market in terms of not the recreational but really providing quality products to professionals.

Cannabis 2.0: A Booming Sector with potential leaders focused on quality product

MGC Pharmaceuticals Ltd (ASX:MXC) is a European based ‘Seed to Medicine’ bio-pharma company focused on developing and commercialising phytocannabinoid derived medicines, is pleased to announce it has received formal approval for the sale of CannEpil® in Ireland following the recommendation by the Health Products Regulatory Authority (HPRA), CannEpil® is one of MGC Pharma’s Investigational Medicinal Product’s (IMP) to treat drug resistant epilepsy. MGC Pharmaceuticals also announced it has signed a binding term sheet (the ‘Term Sheet’) with established Brazilian business services company, BRASILINVEST Global Business and Development (‘BrasilInvest’) to establish a Joint Venture Company (‘JV Co’) for the dedicated retail sales and marketing of MGC Pharma products into key Brazil and Latin American markets. The JV Co is to be incorporated as a 50% (BrasilInvest)/50% (MGC Pharma) ownership structure.

ASX:MXC - MGC Pharmaceuticals expands distribution of CannEpil into Ireland and Brazil

Market transitions and news from a global economy.

hubhopper

Boardroom Media

hubhopper